AIxCrypto Holdings, the company formerly known as Qualigen Therapeutics, has announced a strategic collaboration with Pinnacle Real Estate Group, marking a significant step in its ongoing transformation. The partnership aims to merge artificial intelligence infrastructure with the tokenization of property-backed assets. This move raises the question of whether it can reverse the enduring downward trajectory of the company’s share price.
Regulatory Tailwinds and Sector Momentum
The broader market environment appears favorable for this initiative. In a parallel development on Friday, the U.S. Securities and Exchange Commission (SEC) unveiled an innovation exemption for tokenized securities. This regulatory shift permits limited trading on decentralized platforms, subject to specific conditions including whitelisting and volume caps.
Simultaneously, venture capital is flooding into the sector. Investments in AI-based property technology, or PropTech, surged to $1.7 billion in January, representing a year-over-year increase of 176 percent. This substantial capital inflow provides a strong macroeconomic backdrop for AIxCrypto’s foray into real estate-secured financial instruments.
Partnership Details and Technological Framework
The core of the newly formed alliance focuses on two pillars: the tokenization of real-world assets (RWA) and the deployment of AI systems within real estate applications. Pinnacle Real Estate Group will contribute financial instruments such as property loans, while AIxCrypto supplies the underlying blockchain technology infrastructure. The companies intend to leverage smart contracts and AI agents to streamline transactions and enhance the efficiency and transparency of compliance verification processes.
Market Response and Historical Precedent
The financial markets greeted the news with cautious optimism. On Friday, the company’s shares closed at $1.24, registering a gain of 0.81 percent. In after-hours trading, the stock advanced a further 3.10 percent to reach $1.279. This price movement places the firm’s market capitalization in a range between $7 million and $8.74 million.
Should investors sell immediately? Or is it worth buying Qualigen Therapeutics?
However, investors are advised to consider historical patterns. Following the previous four partnership announcements from the company, its stock price declined by an average of 3.77 percent on the subsequent trading day. This historical context suggests the sustainability of the current positive price reaction remains to be proven.
Broader Strategic Shift and Corporate Investments
Since its restructuring in November 2025, the company has fully committed to integrating AI and blockchain solutions. Its strategic initiatives extend beyond real estate. AIxCrypto recently reported surpassing one million registered wallets on its Hub platform, following a cooperation with the Sei Development Foundation for on-chain identity solutions.
In a separate investment, the company allocated $10 million to Faraday Future. The strategic direction is further supported by an advisory agreement with Yueting Jia, which carries an annual fixed fee of $500,000 supplemented by performance-based stock options.
A note of caution accompanies these ambitions: the full deployment of the on-chain platform for property loans remains contingent upon ongoing regulatory reviews and commercial feasibility assessments. No specific launch date for the first tokenized loan instruments has been disclosed.
Ad
Qualigen Therapeutics Stock: Buy or Sell?! New Qualigen Therapeutics Analysis from February 22 delivers the answer:
The latest Qualigen Therapeutics figures speak for themselves: Urgent action needed for Qualigen Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 22.
Qualigen Therapeutics: Buy or sell? Read more here...
